{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:56:24Z","timestamp":1774403784707,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Evaluation of interim-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT as a prognostic tool in limited disease small cell lung cancer (SCLC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 35 patients with limited disease SCLC from a prospective institutional registry in this retrospective study. Patients received induction chemotherapy (3\u20134 cycles) followed by concurrent radiochemotherapy. Baseline [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT was performed before or shortly after start of induction chemotherapy, interim PET\/CT was acquired during late induction or concurrent chemoradiotherapy. Maximum standardized uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ), metabolic target volume (MTV), and total lesion glycolysis values (TLG) were determined. An exponential decay model with an asymptotic offset was used to describe treatment response over time. Deviations\u2009&gt;\u20092 standard deviations (SD) above model-predicted means after day 30 were considered poor response. Progression-free survival (PFS) was analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients underwent twice-daily radiotherapy to a base dose of 45\u00a0Gy. SUV\n                      <jats:sub>max<\/jats:sub>\n                      showed greater inter-patient variability than MTV. Poor treatment response was observed in 17%, 31%, or 14% at the SUV\n                      <jats:sub>max<\/jats:sub>\n                      , MTV and TLG endpoints. Deviations\u2009&gt;\u20092 SD from the model in SUV\n                      <jats:sub>max<\/jats:sub>\n                      and TLG were significantly associated with shorter PFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0014); MTV was not prognostic (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2630). Leave-one-out cross-validation (LOOCV) could confirm the prognostic value of the standardized residual SUV\n                      <jats:sub>max<\/jats:sub>\n                      larger than 2 standard deviations above model estimate as negative PFS predictor (\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.0152, Fishers exact test).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our decay model enables the characterization of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT response parameters from scans acquired at variable time points during induction chemotherapy and at start of concurrent radiochemotherapy. Poor SUV\n                      <jats:sub>max<\/jats:sub>\n                      or TLG response was predictive of PFS. Interim-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT response may guide individualized treatment adaptation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07658-5","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:05:00Z","timestamp":1763363100000},"page":"3082-3094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[18F]FDG-PET\/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-439X","authenticated-orcid":false,"given":"Christian","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubertus","family":"Hautzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Wiesweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"H\u00f6ing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"K\u00fcrten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Baldes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Nensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustina","family":"Funke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"7658_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","volume":"12","author":"J Yu","year":"2024","unstructured":"Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024;12:799\u2013809. https:\/\/doi.org\/10.1016\/S2213-2600(24)00189-9.","journal-title":"Lancet Respir Med"},{"key":"7658_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","volume":"22","author":"BH Gronberg","year":"2021","unstructured":"Gronberg BH, Killingberg KT, Flotten O, Brustugun OT, Hornslien K, Madebo T, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22:321\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(20)30742-7.","journal-title":"Lancet Oncol"},{"key":"7658_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2404873.","journal-title":"N Engl J Med"},{"key":"7658_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(17)30318-2.","journal-title":"Lancet Oncol"},{"key":"7658_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","volume":"340","author":"AT Turrisi 3rd","year":"1999","unstructured":"Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265\u201371. https:\/\/doi.org\/10.1056\/NEJM199901283400403.","journal-title":"N Engl J Med"},{"key":"7658_CR6","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1200\/JCO.22.01359","volume":"41","author":"J Bogart","year":"2023","unstructured":"Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538. J Clin Oncol. 2023;41:2394\u2013402. https:\/\/doi.org\/10.1200\/JCO.22.01359.","journal-title":"J Clin Oncol"},{"key":"7658_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.32586","volume":"126","author":"X Hu","year":"2020","unstructured":"Hu X, Bao Y, Xu YJ, Zhu HN, Liu JS, Zhang L, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Cancer. 2020;126:840\u20139. https:\/\/doi.org\/10.1002\/cncr.32586.","journal-title":"Cancer"},{"key":"7658_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","volume":"152","author":"C Le Pechoux","year":"2020","unstructured":"Le Pechoux C, Faivre-Finn C, Ramella S, McDonald F, Manapov F, Putora PM, et al. ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiother Oncol. 2020;152:89\u201395. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.012.","journal-title":"Radiother Oncol"},{"key":"7658_CR9","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.1997.15.9.3030","volume":"15","author":"E Work","year":"1997","unstructured":"Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol. 1997;15:3030\u20137. https:\/\/doi.org\/10.1200\/JCO.1997.15.9.3030.","journal-title":"J Clin Oncol"},{"key":"7658_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1023\/a:1012295131640","volume":"12","author":"DV Skarlos","year":"2001","unstructured":"Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic cooperative oncology group (HeCOG). Ann Oncol. 2001;12:1231\u20138. https:\/\/doi.org\/10.1023\/a:1012295131640.","journal-title":"Ann Oncol"},{"key":"7658_CR11","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/annonc\/mdt140","volume":"24","author":"JM Sun","year":"2013","unstructured":"Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013;24:2088\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdt140.","journal-title":"Ann Oncol"},{"key":"7658_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020174","author":"TN Christensen","year":"2021","unstructured":"Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic value of (18)F-FDG-PET parameters in patients with small cell lung cancer: a meta-analysis and review of current literature. Diagnostics. 2021. https:\/\/doi.org\/10.3390\/diagnostics11020174.","journal-title":"Diagnostics"},{"key":"7658_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2011.03.014","volume":"99","author":"J van Loon","year":"2011","unstructured":"van Loon J, Offermann C, Ollers M, van Elmpt W, Vegt E, Rahmy A, et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol. 2011;99:172\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2011.03.014.","journal-title":"Radiother Oncol"},{"issue":"1","key":"7658_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-019-0071-5","volume":"4","author":"TN Christensen","year":"2020","unstructured":"Christensen TN, Langer SW, Villumsen KE, Johannesen HH, Lofgren J, Keller SH. 18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. Eur J Hybrid Imaging. 2020;4(1):2. https:\/\/doi.org\/10.1186\/s41824-019-0071-5.","journal-title":"Eur J Hybrid Imaging"},{"key":"7658_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2967\/jnumed.120.260646","volume":"62","author":"M Guberina","year":"2021","unstructured":"Guberina M, Poettgen C, Metzenmacher M, Wiesweg M, Schuler M, Aigner C, et al. Prognostic value of Post-Induction chemotherapy volumetric Pet\/Ct parameters for stage Iiia\/B Non-Small cell lung cancer patients receiving definitive chemoradiotherapy. J Nucl Med. 2021;62:1684\u201391. https:\/\/doi.org\/10.2967\/jnumed.120.260646.","journal-title":"J Nucl Med"},{"key":"7658_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7658_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1007\/s00259-021-05624-5","volume":"49","author":"SC Vaz","year":"2022","unstructured":"Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, et al. Joint EANM\/SNMMI\/ESTRO practice recommendations for the use of 2-[(18)F]FDG PET\/CT external beam radiation treatment planning in lung cancer V1.0. Eur J Nucl Med Mol Imaging. 2022;49:1386\u2013406. https:\/\/doi.org\/10.1007\/s00259-021-05624-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7658_CR18","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Lang- version 4.0, 2025, AWMF-Registernummer:020-007OLhttps:\/\/www.leitlinienpro-gramm-onkologie.de\/leitlinien\/lungenkarzinom\/; Zugriff am [25.07.2025]. 2025."},{"key":"7658_CR19","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/(sici)1097-0142(19971215)80:12+<2505::aid-cncr24>3.3.co;2-b","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80:2505\u20139. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19971215)80:12+%3C2505::aid-cncr24%3E3.3.co;2-b.","journal-title":"Cancer"},{"key":"7658_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3109\/02841851.2010.497772","volume":"51","author":"YE Huang","year":"2010","unstructured":"Huang YE, Chen CF, Huang YJ, Konda SD, Appelbaum DE. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET\/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol. 2010;51:782\u20138. https:\/\/doi.org\/10.3109\/02841851.2010.497772.","journal-title":"Acta Radiol"},{"key":"7658_CR21","doi-asserted-by":"publisher","unstructured":"van Gomez Lopez O, Garcia Vicente AM, Honguero Martinez AF, Soriano Castrejon AM, Jimenez Londono GA, Udias JM, et al. Heterogeneity in [(1)(8)F]fluorodeoxyglucose positron emission tomography\/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging. Mol Imaging. 2014;13. https:\/\/doi.org\/10.2310\/7290.2014.00032.","DOI":"10.2310\/7290.2014.00032"},{"key":"7658_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343\u20136. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x.","journal-title":"Control Clin Trials"},{"key":"7658_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.007","author":"BH Gronberg","year":"2025","unstructured":"Gronberg BH, Killingberg KT, Flotten O, Bjaanaes MM, Brustugun OT, Madebo T, et al. High-Dose versus Standard-Dose Twice-Daily thoracic radiotherapy in Limited-Stage SCLC: final survival Data, Long-Term Toxicity, and relapse patterns in a Randomized, Open-Label, phase II trial. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.04.007.","journal-title":"J Thorac Oncol"},{"key":"7658_CR24","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.21037\/tlcr-2024-1284","volume":"14","author":"A Herz","year":"2025","unstructured":"Herz A, Guberina M, Pottgen C, Gauler T, Ton TTM, Fischedick G, et al. The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis. Transl Lung Cancer Res. 2025;14:2074\u201388. https:\/\/doi.org\/10.21037\/tlcr-2024-1284.","journal-title":"Transl Lung Cancer Res"},{"key":"7658_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13139-017-0490-9","volume":"52","author":"H Kim","year":"2018","unstructured":"Kim H, Yoo IR, Boo SH, Park HL, O JH, Kim SH. Prognostic value of pre- and post-treatment FDG PET\/CT parameters in small cell lung cancer patients. Nucl Med Mol Imaging. 2018;52:31\u20138. https:\/\/doi.org\/10.1007\/s13139-017-0490-9.","journal-title":"Nucl Med Mol Imaging"},{"key":"7658_CR26","doi-asserted-by":"publisher","first-page":"300060519892419","DOI":"10.1177\/0300060519892419","volume":"48","author":"EK Choi","year":"2020","unstructured":"Choi EK, Park M, Im JJ, Chung YA, Oh JK. Prognostic value of (18)F-FDG PET\/CT metabolic parameters in small cell lung cancer. J Int Med Res. 2020;48:300060519892419. https:\/\/doi.org\/10.1177\/0300060519892419.","journal-title":"J Int Med Res"},{"key":"7658_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00432-019-02848-9","volume":"145","author":"H Chang","year":"2019","unstructured":"Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW. Prognostic significance of metabolic parameters measured by (18)F-FDG PET\/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol. 2019;145:1361\u20137. https:\/\/doi.org\/10.1007\/s00432-019-02848-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7658_CR28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.21147\/j.issn.1000-9604.2018.06.04","volume":"30","author":"L Fu","year":"2018","unstructured":"Fu L, Zhu Y, Jing W, Guo D, Kong L, Yu J. Incorporation of circulating tumor cells and whole-body metabolic tumor volume of (18)F-FDG PET\/CT improves prediction of outcome in IIIB stage small-cell lung cancer. Chin J Cancer Res. 2018;30:596\u2013604. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2018.06.04.","journal-title":"Chin J Cancer Res"},{"key":"7658_CR29","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1200\/JCO.2015.65.5167","volume":"34","author":"C Pottgen","year":"2016","unstructured":"Pottgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N. Standardized uptake decrease on [18F]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA\/B non\u2013small-cell lung cancer. J Clin Oncol. 2016;34:2526\u201333. https:\/\/doi.org\/10.1200\/JCO.2015.65.5167.","journal-title":"J Clin Oncol"},{"key":"7658_CR30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2217\/imt-2021-0341","volume":"14","author":"M Guberina","year":"2022","unstructured":"Guberina M, Guberina N, Pottgen C, Gauler T, Richlitzki C, Metzenmacher M, et al. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy. 2022;14:927\u201344. https:\/\/doi.org\/10.2217\/imt-2021-0341.","journal-title":"Immunotherapy"},{"key":"7658_CR31","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1007\/s00259-021-05204-7","volume":"48","author":"M Guberina","year":"2021","unstructured":"Guberina M, Darwiche K, Hautzel H, Ploenes T, Pottgen C, Guberina N, et al. Impact of EBUS-TBNA in addition to [(18)F]FDG-PET\/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. Eur J Nucl Med Mol Imaging. 2021;48:2894\u2013903. https:\/\/doi.org\/10.1007\/s00259-021-05204-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7658_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21637-y","volume":"12","author":"M Guberina","year":"2022","unstructured":"Guberina M, Herrmann K, Pottgen C, Guberina N, Hautzel H, Gauler T, et al. Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET\/CT. Sci Rep. 2022;12:17511. https:\/\/doi.org\/10.1038\/s41598-022-21637-y.","journal-title":"Sci Rep"},{"key":"7658_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00811-9","volume":"11","author":"H Hautzel","year":"2021","unstructured":"Hautzel H, Alnajdawi Y, Fendler WP, Rischpler C, Darwiche K, Eberhardt WE, et al. N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [(18)F]FDG PET\/CT compared to the histopathology reference standard. EJNMMI Res. 2021;11:68. https:\/\/doi.org\/10.1186\/s13550-021-00811-9.","journal-title":"EJNMMI Res"},{"key":"7658_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.lungcan.2020.08.017","volume":"150","author":"T Berghmans","year":"2020","unstructured":"Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, et al. European cancer organisation essential requirements for quality cancer care (ERQCC): lung cancer. Lung Cancer. 2020;150:221\u201339. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.017.","journal-title":"Lung Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07658-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:14Z","timestamp":1774401974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07658-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7658"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07658-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a study from a retro- and prospective registry. The study was conducted in accordance with the Declaration of Helsinki. The Institutional Ethics committee of our university hospital (Uniklinik Essen) approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish was waived as no individual person\u2019s data is displayed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}